In this study, we found that laricitrin not only enhances DCs’ function, increasing IL-12 and decreasing IL-10 expression, but also switches tumor-promoting Th2 to a tumor-destructive Th1 response in vivo (Figure 6). The gene discussed is IL10; the disease is neoplasm.